Investing.com - Harvard Bioscience (NASDAQ:HBIO) reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Harvard...
Harvard Bioscience (NASDAQ:HBIO) reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $28.8 million versus the consensus...
Meme stocks may be on top of investors’ minds at the moment, but there probably isn’t reason to think that they’ll have a lasting impact. True, trading today...
Harvard Bioscience, Inc. (NASDAQ:HBIO) has been struggling lately, but the selling pressure may be coming to an end soon. That is because HBIO recently saw a Hammer Chart Pattern...
For Immediate ReleaseChicago, IL – April 25, 2018 - Stocks in this week’s article TheStreet, Inc. (NASDAQ:TST) , The Joint Corp. (NASDAQ:JYNT) , Harvard Bioscience,...
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
|Average||3.900 (+65.96% Upside)|
|No. of Analysts||3|